CAI 8-K: Company Furnishes Q2 2025 Earnings Release as Exhibit 99.1

Rhea-AI Filing Summary

Caris Life Sciences, Inc. filed a Form 8-K dated August 12, 2025 stating that the company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company expressly states the press release is furnished, not "filed," and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings except as expressly noted.

The report is signed by Luke Power, Senior Vice President, Chief Financial Officer and Chief Accounting Officer. The filing identifies the company’s common stock as trading under the symbol CAI on The Nasdaq Stock Market and indicates the registrant is an emerging growth company. For the actual financial figures, readers must consult the furnished press release in Exhibit 99.1.

Positive

• Press release announcing Q2 2025 results was furnished as Exhibit 99.1, providing timely disclosure to the market.
• Inline XBRL cover page included as Exhibit 104, indicating structured data support for interactive review.

Negative

• The press release is furnished, not filed, which the company states limits Section 18 liability.
• The 8-K does not include the actual financial figures

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished; 8-K contains no financial detail itself, directing investors to Exhibit 99.1 for Q2 results.

The filing notifies investors that a press release announcing results for the quarter ended June 30, 2025 was issued and furnished as Exhibit 99.1, with an Inline XBRL cover page included as Exhibit 104. The company clarifies the release is furnished rather than filed, limiting Section 18 liability. This is a standard operational disclosure that preserves formal reporting rights while providing timely access to results via the press release.

Corporate Governance Expert

TL;DR: Disclosure complies with Form 8-K presentation norms; furnished status reduces filing liability and signature by CFO confirms proper authorization.

The document follows routine 8-K practice by furnishing the earnings press release (Exhibit 99.1) and including Inline XBRL data (Exhibit 104). The explicit statement that the release is furnished, not filed, is a legal distinction that limits Section 18 liability and potential incorporation by reference. The report is executed by the company’s CFO, indicating corporate authorization of the disclosure. No substantive financial metrics are included in the 8-K itself.

08/12/2025 - 04:10 PM

0002019410FALSE00020194102025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 8-K

_______________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

CARIS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Texas

001-42706

85-2077369

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

750 W. John Carpenter Freeway Suite 800  Irving, TX						75039
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (866) 771-8946

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :

☐						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CAI

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, Caris Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein solely for purposes of this Item 2.02 disclosure.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release issued August 12, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 12, 2025
			CARIS LIFE SCIENCES, INC.
			By:			/s/ Luke Power
			Name:			Luke Power
			Title:			Senior Vice President, Chief Financial Officer and Chief Accounting Officer

FAQ

What did Caris Life Sciences (CAI) disclose in this Form 8-K?

Caris Life Sciences disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025, furnished as Exhibit 99.1 to the Form 8-K.

Is the press release in the 8-K considered filed or furnished?

The press release is expressly furnished, not filed, and the company states it is therefore not subject to Section 18 liabilities or incorporated by reference except as expressly noted.

Which quarter do the results cover in the disclosed press release?

The press release covers the quarter ended June 30, 2025.

Where can I find the financial figures referenced by the 8-K?

The Form 8-K itself does not include financial figures; the detailed results are in the press release furnished as Exhibit 99.1.

Who signed the Form 8-K for Caris Life Sciences (CAI)?

Luke Power, Senior Vice President, Chief Financial Officer and Chief Accounting Officer, signed the Form 8-K dated August 12, 2025.